ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment

Che, Wensheng; Zhao, Ming; Li, Xiaoqing; Li, Chunlong*; Cho, William C.*; Yu, Shan*哈尔滨医科大学; 1
Frontiers in Endocrinology2022-11-29DOI: 10.3389/fendo.2022.1002916
2被引16阅读
引用收藏
分享

摘要

There is a continuously rising incidence of non-alcoholic fatty liver disease (NAFLD) around the world, which parallels the increasing incidence of metabolic diseases. NAFLD is a range of liver conditions that contains simple non-alcoholic fatty liver and advanced non-alcoholic steatohepatitis. In serious cases, NAFLD may develop into cirrhosis or even liver cancer. NAFLD has an intense relationship with metabolic syndrome, type 2 diabetes mellitus. It is known that gut microbiota, and functional molecules such as adenosine monophosphate-activated protein kinase JNK, and peroxisome proliferator-activated receptors (PPARs) in progressing and treating NAFLD. Traditionally, the conventional and effective therapeutic strategy is lifestyle intervention. Nowadays, new medicines targeting specific molecules, such as farnesoid X receptor, PPARs, and GLP-1 receptor, have been discovered and shown beneficial effects on patients with NAFLD. In this article, we focus on the molecular mechanisms and therapeutic approaches to NAFLD.

学科与关键词

关键词
non-alcoholic fatty liver disease (NAFLD)non-alcoholic steatohepatitis (NASH)gut microbiotametabolic diseasesadenosine monophosphate-activated protein kinase
相关
加载中…
  • Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
    Chen, Hui-Ting; Huang, Hong-Li; Li, Yong-Qiang; Xu, Hao-Ming; Zhou, Yong-Jian*WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26(16): 1901-1911.被引 30
  • Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies
    Wang, Guang-Yan; Zhang, Xiao-Yan; Wang, Chun-Jiong; Guan, You-Fei*WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29(1): 75-95.被引 3
  • A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
    Zhou, Shipeng; You, Huimin; Qiu, Shuting; Yu, Dawei; Bai, Yan; He, Jincan; Cao, Hua; Che, Qishi; Guo, Jiao*; Su, Zhengquan*Biomedicine and Pharmacotherapy, 2022, 154: 113577.被引 16
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2022-11-29
卷期
第 13 卷
页码
1002916
DOI
10.3389/fendo.2022.1002916
期刊等级
3区
成果收录
SCIE
资助标注
Postdoctoral Scientific Research Developmental Fund; [LBH-Q20112]

作者

  • C

    Che, Wensheng (第一作者)

    2 · harbin med univ

  • Z

    Zhao, Ming

    chengdu med coll · 1

查看全部 6 位作者收起作者
  • L

    Li, Xiaoqing

    2 · harbin med univ

  • L

    Li, Chunlong (通讯)

    2 · harbin med univ

  • C

    Cho, William C. (通讯)

  • Y

    Yu, Shan (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417